Cann Group
Michael Long is an experienced professional in operations and management, currently serving as the General Manager of Operations at Cann Group since January 2024. Prior roles include General Manager for Australia at Palla Pharma Limited from September 2021 to September 2023, and Chief Operating Officer at Wingara AG Limited from September 2020 to June 2021. Long has a substantial background in agricultural leadership with positions such as Director of Agriculture at Palla Pharma Limited (January 2017 - September 2020) and Managing Director at LGL Commodities Pry Ltd (January 2010 - June 2014). Additional experience includes General Manager roles at Sigma Healthcare and AWB Limited. Michael Long's educational qualifications include a Graduate Diploma in Agribusiness from Monash University and a B.Sc. in Agronomy, Horticulture, and Plant Pathology from the University of New England, along with various leadership programs and certifications.
This person is not in any teams
Cann Group
Cann Group is a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and approved export markets. Cann has established research, cultivation and GMP manufacturing facilities in Bundoora, in northern Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group’s leading position in plant genetics, breeding, extraction, analysis and production techniques supports its objective to supply high quality, safe medicinal cannabis for a range of diseases and medical conditions. Incorporated in the Company's brand portfolio is its proprietary Satipharm delivery system for cannabinoids. Botanitech is a brand created by Cann and boasts a diverse, affordable and high-quality product range. The first stage of our new, state-of-the-art facility in regional Victoria is fully operational, with in-house analytical chemistry and microbiology laboratories, and the capacity to produce 12,500kg of high-quality flower per year, with subsequent stages planned in response to growing demand. We have extensive R&D collaborations with globally renowned agricultural and pharmaceutical research partners, and have developed our own exclusive, proprietary lines of high-yielding cultivars. Cann Group is committed to the future of high-quality, low-cost cannabis medicines, and the development of a reliable and trusted industry.